Risk of Hepatocellular Carcinoma in Diabetic Patients and Risk Reduction Associated With Anti-Diabetic Therapy: A Population-Based Cohort Study
The American Journal of Gastroenterology2011Vol. 107(1), pp. 46–52
Citations Over TimeTop 1% of 2011 papers
Abstract
Comorbidity with cirrhosis and/or hepatitis appears to be associated with an extremely increased risk of developing HCC among DM patients. These high-risk patients should be closely monitored for HCC. The use of metformin or thiazolidinediones may reduce the risk of developing HCC.
Related Papers
- → Cohort Profile: The Epidemiology of Chronic Diseases and Multimorbidity. The EpiChron Cohort Study(2017)84 cited
- Clinicopathologic features and risk factors for hepatocellular carcinoma: results from a single center in southern Turkey.(2003)
- → Profile of vitamin D in a cohort of physicians and diabetologists in Kolkata(2012)23 cited
- Pathology of hepatocellular carcinoma(2006)
- → Cohort profile: COVID-19 in a cohort of pregnant women and their descendants, the MOACC-19 study(2020)